Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:22 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 14,119 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating the Impact of Training for IHSS Workers

NCT06205433
View directory record Official record
Conditions
Home Care for Elderly or Disabled Individuals
Interventions
IHSS Basic Training
Other
Lead sponsor
Abdul Latif Jameel Poverty Action Lab
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Results available

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

NCT04975438
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Active, not recruiting Phase 2 Interventional

Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration

NCT02862938
View directory record Official record
Conditions
Glaucoma
Interventions
NT-501 ECT implant, Sham
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

NCT05629338
View directory record Official record
Conditions
Coagulopathy, Hemorrhage
Interventions
Autologous Spray Dried Plasma
Combination Product
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Not yet recruiting Not applicable Interventional

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

NCT07405138
View directory record Official record
Conditions
Chalazion
Interventions
Sham IPL, Active IPL
Device
Lead sponsor
Lumenis Be Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of VP20621 for Prevention of Recurrent Clostridium Difficile Infection

NCT01259726
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
VP20621, Placebo
Biological · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Modesto, California • Palm Desert, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Nov 3, 2026, 7:22 AM EST
Recruiting Phase 3 Interventional

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT07743463
View directory record Official record
Conditions
Obesity, Overweight, Chronic Weight Management
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional

A Trial Assessing the Safety and Feasibility of Respiratory Muscle Training and Exercise Training in Children and Adolescents With Persistent Asthma

NCT03911206
View directory record Official record
Conditions
Asthma
Interventions
Inspiratory muscle training (IMT), Exercise alone, IMT and Exercise
Behavioral
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study for Abused Chinese Immigrant Women

NCT05011552
View directory record Official record
Conditions
Intimate Partner Violence, Depression, Anxiety, PTSD
Interventions
Self-Compassion, Health, and Empowerment (SHE), The Control Condition
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

NCT04483947
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide (HMR1726)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
4
States / cities
Maitland, Florida • Fort Wayne, Indiana • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

NCT05586958
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
36
States / cities
Birmingham, Alabama • Covina, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of an IMB-based Intervention for Reducing Sweetened Beverages Consumption in Preschool Children

NCT03957148
View directory record Official record
Conditions
Childhood Obesity
Interventions
Sugar-sweetened beverage reduction education for preschool children
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Nov 3, 2026, 7:22 AM EST
Recruiting Phase 2 Interventional

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

NCT06812078
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
TAK-360, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Redwood City, California • Santa Ana, California • Colorado Springs, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study for Safety of ACHN-490

NCT00822978
View directory record Official record
Conditions
Healthy
Interventions
ACHN-490 Injection vs placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Nov 3, 2026, 7:22 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

BabyQ's: Randomized Controlled Trial of Health Messaging in Pregnancy and Infancy

NCT04238585
View directory record Official record
Conditions
Pregnancy Related, Infant Development
Interventions
Mobile messaging
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation

NCT01066585
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin Cream, vehicle control
Drug
Lead sponsor
Topaz Pharmaceuticals Inc
Industry
Eligibility
6 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
Yuma, Arizona • Dinuba, California • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2012 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

NCT03207425
View directory record Official record
Conditions
NASH
Interventions
EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional Results available

A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease

NCT03520998
View directory record Official record
Conditions
Alzheimer Disease, Mild to Moderate Alzheimer Disease
Interventions
GRF6019
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Lemon Grove, California • Long Beach, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 3, 2026, 7:22 AM EST
Terminated Phase 3 Interventional Results available

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

NCT04729387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional

A Study to Assess the Efficacy, Safety, and Tolerability of Oral NORA520 in Adults With Severe Postpartum Depression

NCT06285916
View directory record Official record
Conditions
Depression, Postpartum, Postpartum Depression, Post-partum Depression, Postnatal Depression, Post-Natal Depression
Interventions
NORA520 Dose 1, NORA520 Dose 2, Placebo
Drug
Lead sponsor
TWi Biotechnology, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Bentonville, Arkansas • Anaheim, California • Canoga Park, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 2 Interventional Results available

A Study of TAK-861 in Participants With Narcolepsy Type 2

NCT05687916
View directory record Official record
Conditions
Narcolepsy Type 2
Interventions
Placebo, TAK-861 2 mg, TAK-861 2 mg and 5 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
16 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
22
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

NCT01282684
View directory record Official record
Conditions
Healthy
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Nov 3, 2026, 7:22 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 7:22 AM EST